CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CAR-T 细胞治疗后急性脊髓病的临床特征、病理生理学与管理
英文原题：Clinical features, pathophysiology, and management of acute myelopathy following CAR T-cell therapy.
查看英文原题
Clinical features, pathophysiology, and management of acute myelopathy following CAR T-cell therapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
嵌合抗原受体（CAR）T细胞疗法已经彻底改变了复发/难治性血液系统恶性肿瘤患者的治疗，但它伴随着独特的不良反应，尤其是细胞因子释放综合征和ICANS（免疫效应细胞相关神经毒性综合征）。随着CAR-T 细胞疗法经验的积累，一些独特且少见神经系统并发症正变得越来越明显。近年来，关于CAR-T 细胞疗法给药后发生急性脊髓病的报道不断增多。尽管已经建立了管理ICANS的共识指南，但对于这一罕见并发症的适当检查和治疗仍缺乏指导。在本手稿中，我们深入探讨CAR-T 细胞疗法后急性脊髓炎的临床特征、病理生理学及最佳管理策略，并从文献中已报道的病例中汲取见解。
展开英文摘要原文
Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of patients with relapsed or refractory hematologic malignancies, but it comes with unique toxicities, notably cytokine release syndrome and ICANS (immune effector cell-associated neurotoxicity syndrome). As experience with CAR T-cell therapy grows, distinct and infrequent neurologic complications are becoming increasingly evident.
Recently, reports of acute myelopathy after the administration of CAR T-cell therapies have been accumulating. Despite the establishment of consensus guidelines for managing ICANS, there remains limited guidance on the appropriate investigations and treatments for this rare complication. In this manuscript, we delve into the clinical features, pathophysiology, and strategies for the optimal management of acute myelitis after CAR T-cell therapy and draw insights from reported cases in the literature.
论文信息
- 作者
- Deschênes-Simard X、Santomasso BD、Dahi PB
- 单位
- Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.United States
- 文献类型
- 综述
- 期刊
- Blood2024 Nov 14
- 原文标识
- PubMed 39226460 · DOI 10.1182/blood.2024025679